“Our ability to affect change through our involvement on the Finance and Tax Committee at BIO has been extremely beneficial to us as a small cap public biotech company. In particular, BIO was able to add a revenue requirement for SOX 404(b) qualification. Accordingly, along with our other small cap biotech peers, we will be able to further delay implementing this costly and burdensome regulation."
Marc Belsky
Chief Financial Officer
Kezar Life Sciences